

2Q25 Qtrly Activity Report updated

10 February 2025

Anagenics Limited (ASX: AN1, “Anagenics” or the “Company”) today provides an update on payment to related parties as shown in section 6 of Appendix 4C for the quarter ended 31 December 2024, an aggregate amount of \$65k was paid to related parties and their associates, which includes wages and fees inclusive of GST paid to former directors and their associates, (\$116k was paid in Q1 FY2025).

Please refer to enclosed updated activity report for the quarter ended 31 Dec 2024.

This announcement was authorised by the Board of Anagenics Limited.

For further information, please contact:

Sandy Beard
Chair, Anagenics Limited
P: 0412 308 263
E: sandy@xvgroup.com.au

Anagenics Limited (ASX: AN1)

Anagenics is a health, beauty, and wellness business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products.

For further information, please see www.anagenics.com

2Q25 Qtrly Activity Report

10 February 2025

Anagenics Limited (ASX:AN1, “Anagenics” or the “Company”) today provides an update on activities for the quarter ended 31 December 2024 (“2Q25”).

The quarter highlights the impact of restructuring activities and resetting of the monthly cost base. Net Operating Cash Flow achieved an outflow of \$0.3m relative to an outflow of \$0.9m in the previous quarter (1Q25) and significant reduction in the monthly and annual cost base, whilst operating within the reduced revenue base resulting from divestment of Face Medi. Sales of the core BLC Cosmetics business have continued largely unaffected by the restructuring activities.

This improvement was driven by a large reduction in cash payments to suppliers & employees as a result of the previously-disclosed business restructuring, which took effect from late October 2024.

Key cost reductions included:

- Advertising and marketing expenses down 45% to \$124k (1Q25: \$224k);
- Staff & Director Costs down 42% to \$409k (1Q25: \$705k); and
- Admin and Corporate costs down 66% to \$156k (1Q25: \$455k).

The full benefits of the restructure will be realised in 3Q25.

Payment to related parties during the quarter ended 31 December 2024 (“2Q25”).

As shown in section 6 of Appendix 4C for the quarter ended 31 December 2024, an aggregate amount of \$65k was paid to related parties and their associates, which includes wages and fees inclusive of GST paid to former directors and their associates, (\$116k was paid in Q1 FY2025).

Voluntary Suspension

Per the Company's market announcement on 10 January 2025, efforts to enable the reinstatement of its securities to quotation continue and this process is expected to be completed by the end of February 2025.

This announcement was authorised by the Board of Anagenics Limited.

For further information, please contact:

Sandy Beard
Chair, Anagenics Limited
P: 0412 308 263
E: sandy@xvgroup.com.au

Anagenics Limited (ASX:AN1)

Anagenics is a health, beauty, and wellness business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products.

For further information, please see www.anagenics.com